You are here:

Archived: aliskiren (Rasilez)

Advice

In the absence of a submission from the holder of the marketing authorisation

aliskiren (Rasilez) is not recommended for use within NHSScotland for the treatment of essential hypertension.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: aliskiren (Rasilez)
SMC Drug ID: 462/08
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: for the treatment of essential hypertension
BNF Category:
Sub Category: 2.6 Nitrates*** calcium-channel blockers*** and other antianginal drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 May 2008

Current Advice

Resubmission 8 February 2010

Archived Advice

Full submission 12 January 2009

Back